CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0851

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro ; volume:68 ; number:8 ; day:22 ; month:7 ; year:2019 ; pages:1359-1368 ; date:8.2019
Cancer immunology immunotherapy ; 68, Heft 8 (22.7.2019), 1359-1368, 8.2019

Creator: Rosskopf, Sandra
Leitner, Judith
Zlabinger, Gerhard J.
Steinberger, Peter

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-019-02369-x

URN: urn:nbn:de:101:1-2019122801584245779332

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Rosskopf, Sandra
Leitner, Judith
Zlabinger, Gerhard J.
Steinberger, Peter
SpringerLink (Online service)

Other Objects (12)

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Hochschulschrift

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells

Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription

m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus

CD160 isoforms and regulation of CD4 and CD8 T-cell responses

Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens

Related objects

Reset password